Continuing Medical Education
Imedex, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Imedex, LLC designates this educational activity for a maximum 1.25 of AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Who Should Attend
This educational activity is specifically designed for hematologists, oncologists, internists and other physicians, physicians-in-training, and healthcare professionals (nurses, pharmacists) involved and/or interested in lymphoma, myeloma and related plasma cell disorders and their management.
Objectives
After successful completion of this educational activity, attendees should be able to:
- Discuss emerging therapies in the pipeline for the treatment of lymphoproliferative disorders
- Assess the emerging role of immunomodulatory agents in the treatment of multiple myeloma,
chronic lymphocytic leukemia, and non-Hodgkin’s lymphoma
- Interpret recent results with the use of immunomodulatory agents for the treatment of hematologic malignancies
- Identify future directions with the use of immunomodulatory agents in hematologic malignancies
Asher A. Chanan-Khan, MD
Department of Medicine
School of Medicine & Biomedical Science
Roswell Park Cancer Institute
Buffalo, New York
Morton Coleman, MD
Center for Lymphoma and Myeloma
Weill Cornell Medical College
New York Presbyterian Hospital
New York, New York
Paul A. Hamlin, MD
Memorial Sloan-Kettering Cancer Center
New York, New York
Jeffrey A. Zonder, MD
Karmanos Cancer Institute
Detroit, Michigan
Friday, October 17, 2008
11:15 am
Assembly and Lunch
11:35 am
Introductions & opening remarks
Ruben Niesvizky, MD
11:40 am
Exploring the mechanisms of activity of IMiD® compounds
Asher A. Chanan-Khan, MD
11:55 am
Q&A
12:00 am
Evolution in the therapeutic landscape for multiple myeloma
Jeffrey A. Zonder, MD
12:15 pm
Q&A
12:20 pm
Emerging novel therapies for aggressive non-Hodgkin’s lymphomas
Paul A. Hamlin, MD
12:35 pm
Q&A
12:40 pm
Expanding the therapeutic options in CLL
Asher A. Chanan-Khan, MD
12:55 pm
Q&A
1:00 pm
Adjourn